Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
Want to see IN:MANGALAM full AI Analyst Report?
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹94.80
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹480.86M
Enterprise Value₹1.52B
Total Cash (Recent Filing)₹96.75M
Total Debt (Recent Filing)₹949.21M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.51
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.19
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche B2B Specialty ChemicalsMangalam operates in specialty pharmaceutical intermediates, a B2B segment with technical barriers and sticky customer relationships. This business model supports durable demand from drug makers and typically enables contract visibility, repeat orders, and relative pricing stability over months.
Demonstrated Cash-generation In Prior YearsThe company has produced meaningful operating cash flow in earlier years, showing operational capability to convert sales to cash when conditions improve. That track record improves credibility of a potential multi-quarter recovery in working-capital management and cash generation ability if volumes or margins rebound.
Positive Equity And Sizeable AssetsDespite recent stress, the balance sheet retains positive equity and sizeable assets, giving a structural cushion. That asset base supports creditor confidence, potential refinancing options, or asset-backed working capital solutions that preserve operational continuity over the medium term.
Bears Say
Large FY2026 Loss & Margin DeteriorationA material swing to large FY2026 losses and negative operating margins signals structural pressure on profitability. Sustained margin erosion limits internal reinvestment, weakens pricing leverage, and raises the bar for operational fixes needed to restore multi-quarter profitability and protect cash.
Weak And Inconsistent Cash FlowNegative operating cash flow and deeply negative free cash flow in FY2026 create tangible funding pressure. Persistent cash deficits reduce flexibility for capex, working capital, and debt repayment, increasing the likelihood of external financing or tighter liquidity management over coming quarters.
Rising Leverage Reduces FlexibilityA meaningful rise in leverage to ~1.02 increases interest and covenant risks and narrows strategic options. Higher debt amplifies earnings volatility impact on solvency and can constrain investment or recovery initiatives, making a sustained operational turnaround more difficult to execute.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹94.80 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹480.86M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 78 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on May 14, 2026. The company reported -₹8.48 earnings per share for the quarter, missing the consensus estimate of N/A by -₹8.48.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹8.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.311%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Par Drugs and Chemicals Limited
―
Vaishali Pharma Ltd.
―
Vivimed Labs Limited
―